SETD2 and lung cancer: In lung cancer, mutations or deletions of SETD2 lead to decreased H3K36me3 levels, triggering replication stress, DNA mismatch repair defects, and genomic instability, thereby promoting tumor heterogeneity and drug resistance (202).